Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $21 from $23 and keeps a Buy rating on the shares. The firm remains “enthusiastic” about ENTR-601-44 and ENTR-601-45 following Entrada’s Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
- Entrada Therapeutics reports Q1 EPS (42c), consensus (77c)
- Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals
- Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment
- Entrada Therapeutics Gains UK Approval for DMD Study